News
Novo Nordisk to sell weight-loss drug for $499
Digest more
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...
Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback